Mitochon Pharmaceuticals » Logo

MP-101 and MP-201 Glaucoma Exploratory Research Grant Awarded to University of Montreal by BrightFocus Foundation in Collaboration with Mitochon Pharmaceuticals

Mitochon is delighted to expand upon our mitochondrial targeted approach in vision loss with the initial MP201 striking findings in optic neuritis (pre-MS) protecting retinal ganglion cells (RGC) and preventing demyelination of optic nerve (lab of Dr. Kenneth Shindler, MD Scheie Eye Institute, Penn Med). Now we are turning our attention to applications in glaucoma, a devastating loss of vision likely rooted in mitochondrial dysfunction. The BrightFocus Foundation is funding our proposal, “Disease-modifying mitochondrial uncouplers: a new therapeutic strategy for glaucoma”.  We are very fortunate that this two year study will be performed at the laboratory of world renowned glaucoma scientist, Dr. Adriana Di Polo, Ph.D. at the University of Montreal Hospital Research Center. The focus of the study is largely based upon MP101 and MP201’s mechanism of action correcting calcium handling, while upregulating brain-derived neurotrophic factor (BDNF), a powerful survival factor for injured RGCs.

About Mitochon Pharmaceuticals
Mitochon was founded in 2014 with the mission to develop treatments for insidious diseases through the modulation of mitochondrial physiology, with applications to neurodegeneration, neuromuscular, and developmental diseases. Mitochon’s lead programs, MP101 and MP201, specifically harnesses the power of the mitochondria to provide broad neural protection. These compounds elicit mild increases in energy expenditure that result in strengthening cellular survival—similar to the positive effects seen with fasting and exercise. These compounds also induce an important neurotrophin, Brain Derived Neurotrophic Factor (BDNF), involved in cognition and neural growth. Mitochon is supported by Ben Franklin Technology Partners Southeastern PA, an initiative of the Pennsylvania Department of Community and Economic Development funded by the Ben Franklin Technology Development Authority.